Varun Govil
Algemeen Directeur bij Epinoma, Inc.
Profiel
Varun Govil is currently working as a Venture Partner at Pioneer Fund and as Secretary, Chief Executive & Financial Officer at Epinoma, Inc. He completed his undergraduate degree from the University of California San Diego in 2020.
Actieve functies van Varun Govil
| Bedrijven | Functie | Begin |
|---|---|---|
Epinoma, Inc.
 Epinoma, Inc. BiotechnologyHealth Technology Epinoma, Inc. is an early-stage biotechnology company based in San Carlos, CA. The company is developing a novel method to quantify epigenetic signals for early-stage cancer detection and minimal residual disease (MRD) monitoring. The company has received early backing from renowned Harvard geneticist Dr. George Church and has established a strong research collaboration with researchers at TU Dortmund. Epinoma plans to onboard early access liquid biopsy and biopharma customers in late 2022. The CEO of the company is Varun Govil. | Algemeen Directeur | - |
Pioneer Fund/NY/
 Pioneer Fund/NY/ Investment ManagersFinance Pioneer Fund/NY/ is a venture capital firm founded by Jason Gray. The firm is headquartered in San Francisco, California. | Private Equity Investor | - |
Opleiding van Varun Govil
| University of California San Diego | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Pioneer Fund/NY/
Pioneer Fund/NY/ Investment ManagersFinance Pioneer Fund/NY/ is a venture capital firm founded by Jason Gray. The firm is headquartered in San Francisco, California. | Finance |
Epinoma, Inc.
Epinoma, Inc. BiotechnologyHealth Technology Epinoma, Inc. is an early-stage biotechnology company based in San Carlos, CA. The company is developing a novel method to quantify epigenetic signals for early-stage cancer detection and minimal residual disease (MRD) monitoring. The company has received early backing from renowned Harvard geneticist Dr. George Church and has established a strong research collaboration with researchers at TU Dortmund. Epinoma plans to onboard early access liquid biopsy and biopharma customers in late 2022. The CEO of the company is Varun Govil. | Health Technology |
